Asset Details
Do you wish to reserve the book?
Syringic acid loaded chitosan nanoparticles mitigate glycation associated oxidative stress and inflammation in hyperglycaemic rat model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Syringic acid loaded chitosan nanoparticles mitigate glycation associated oxidative stress and inflammation in hyperglycaemic rat model
Do you wish to request the book?
Syringic acid loaded chitosan nanoparticles mitigate glycation associated oxidative stress and inflammation in hyperglycaemic rat model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Syringic acid loaded chitosan nanoparticles mitigate glycation associated oxidative stress and inflammation in hyperglycaemic rat model
2025
Overview
Syringic acid (SA), a phenolic compound, is found naturally in several plants, fruits, and vegetables and has numerous therapeutic attributes. The objective of the research was to investigate the possible impact of syringic acid nanoparticles (SANPs) on hyperglycemia, particularly in relation to advanced glycation end products, reactive oxygen species, and inflammation. SANPs were prepared by ionic gelation method and characterized. Rats were divided into 5 groups, normal control, high-fat and high-fructose diet (HFFD), HFFD + metformin (120 mg/kg), HFFD + SA (30 mg/kg) and HFFD + SANPs (15 mg/kg). Rats showed a remarkable decrease in body weight (↓31.61%) and fasting blood glucose levels (↓62.63%) in HFFD + SANPs group. The HbA1c decreased from 5.8 ± 0.05% in HFFD to 4.4 ± 0.12% in HFFD + SA and 4.1 ± 0.16% in HFFD + SANPs treatment groups. The administration of SANPs resulted in a considerable improvement (
p
< 0.001) in the activity of glyoxalase-1 (Glo1, 0.19 ± 0.003 U/mg protein), glyoxalase-2 (Glo2, 0.14 ± 0.002 U/mg protein) and hexokinase-2 (29.19 ± 2.24 ng/dL). There was a significant decrease (
p
< 0.001) in malondialdehyde (MDA) levels along with increased glutathione (GSH), superoxide-dismutase (SOD) and catalase activity. The in-silico analysis indicated potential binding affinities with hexokinase 2 (-5.4), IL-6 (-5.7), catalase (-5.8), MDA (-5.4) and GSH (-5.1). Furthermore, these interventions resulted in enhancements in the plasma concentrations of lipid profile components as well as improvements in liver function tests and expression of pro-inflammatory cytokines including IL-6, IL-8 and NF-κB. Utilization of SANPs holds promise as a therapeutic strategy for mitigating hyperglycemia.
Publisher
Nature Publishing Group UK,Nature Portfolio
Subject
/ Animals
/ Fructose
/ Gallic Acid - administration & dosage
/ Gallic Acid - analogs & derivatives
/ Glycation End Products, Advanced - metabolism
/ Glycosylation - drug effects
/ Humanities and Social Sciences
/ Hyperglycemia - drug therapy
/ Male
/ Nanoparticles - administration & dosage
/ Oxidative Stress - drug effects
/ Rats
/ Science
We currently cannot retrieve any items related to this title. Kindly check back at a later time.